322 related articles for article (PubMed ID: 18580502)
21. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
22. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder.
Pliszka SR; Matthews TL; Braslow KJ; Watson MA
J Am Acad Child Adolesc Psychiatry; 2006 May; 45(5):520-526. PubMed ID: 16670648
[TBL] [Abstract][Full Text] [Related]
23. Ten years of experience with 1,000 hyperactive children in a private practice.
Eichlseder W
Pediatrics; 1985 Aug; 76(2):176-84. PubMed ID: 4022690
[TBL] [Abstract][Full Text] [Related]
24. [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)].
Stasik D; Tucha O; Tucha L; Walitza S; Lange KW
Psychiatr Pol; 2009; 43(2):183-92. PubMed ID: 19697788
[TBL] [Abstract][Full Text] [Related]
25. Stimulant medication effects in a summer treatment program among young children with attention-deficit/hyperactivity disorder.
Chacko A; Pelham WE; Gnagy EM; Greiner A; Vallano G; Bukstein O; Rancurello M
J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):249-57. PubMed ID: 15725969
[TBL] [Abstract][Full Text] [Related]
26. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
Janols LO; Liliemark J; Klintberg K; von Knorring AL
Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
[TBL] [Abstract][Full Text] [Related]
27. Methylphenidate: growth retardation.
Prescrire Int; 2011 Oct; 20(120):238-9. PubMed ID: 21970086
[TBL] [Abstract][Full Text] [Related]
28. ADHD and growth: anthropometric changes in medicated and non-medicated ADHD boys.
Ptacek R; Kuzelova H; Paclt I; Zukov I; Fischer S
Med Sci Monit; 2009 Dec; 15(12):CR595-9. PubMed ID: 19946228
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
Faraone SV; Glatt SJ
J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
[TBL] [Abstract][Full Text] [Related]
30. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
31. [Influence of methylphenidate on growth of school age children with attention deficit hyperactivity disorder].
Zhang HY; Du ML; Zhuang SQ; Liu MN
Zhonghua Er Ke Za Zhi; 2005 Oct; 43(10):723-7. PubMed ID: 16255846
[TBL] [Abstract][Full Text] [Related]
32. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A; Richard C; Prinzo R; Binder C
Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
[TBL] [Abstract][Full Text] [Related]
33. Stimulant treatment of adult attention-deficit/hyperactivity disorder.
Spencer T; Biederman J; Wilens T
Psychiatr Clin North Am; 2004 Jun; 27(2):361-72. PubMed ID: 15064002
[TBL] [Abstract][Full Text] [Related]
34. Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy.
Rao JK; Julius JR; Breen TJ; Blethen SL
Pediatrics; 1998 Aug; 102(2 Pt 3):497-500. PubMed ID: 9685452
[TBL] [Abstract][Full Text] [Related]
35. Stimulant medications.
Greenhill LL; Halperin JM; Abikoff H
J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):503-12. PubMed ID: 10230181
[TBL] [Abstract][Full Text] [Related]
36. Paying attention to stimulants: height, weight, and cardiovascular monitoring in clinical practice.
Towbin K
J Am Acad Child Adolesc Psychiatry; 2008 Sep; 47(9):977-80. PubMed ID: 18580503
[No Abstract] [Full Text] [Related]
37. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
[No Abstract] [Full Text] [Related]
38. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
[TBL] [Abstract][Full Text] [Related]
39. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
40. Dexmethylphenidate for attention deficit hyperactivity disorder.
Coury D
Expert Opin Pharmacother; 2009 Nov; 10(16):2679-85. PubMed ID: 19874250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
